Delcath Systems (NASDAQ:DCTH) Research Coverage Started at Stephens

Stephens assumed coverage on shares of Delcath Systems (NASDAQ:DCTH – Get Free Report) in a report released on Tuesday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $25.00 price target on the stock. Stephens’ price target indicates a potential upside of 247.71% from the company’s current price.

A number of other equities analysts have also recently weighed in on DCTH. HC Wainwright boosted their price target on Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, March 27th. StockNews.com raised shares of Delcath Systems to a “sell” rating in a research note on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.20.

Get Our Latest Analysis on DCTH

Delcath Systems Trading Up 1.7 %

Shares of NASDAQ DCTH opened at $7.19 on Tuesday. The company’s 50-day moving average price is $4.96 and its 200 day moving average price is $4.17. Delcath Systems has a 52 week low of $2.25 and a 52 week high of $7.99. The stock has a market cap of $199.74 million, a price-to-earnings ratio of -2.42 and a beta of 0.55.

Delcath Systems (NASDAQ:DCTH – Get Free Report) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.19. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 563.60%. The business had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $0.48 million. During the same period last year, the company posted ($0.86) EPS. As a group, research analysts expect that Delcath Systems will post -1.45 earnings per share for the current year.

Insider Transactions at Delcath Systems

In other Delcath Systems news, Director Gil Aharon bought 26,882 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was purchased at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the purchase, the director now owns 1,069,710 shares of the company’s stock, valued at approximately $3,979,321.20. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 17.94% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of DCTH. Vivo Capital LLC boosted its position in shares of Delcath Systems by 57.4% in the third quarter. Vivo Capital LLC now owns 1,855,191 shares of the company’s stock worth $7,514,000 after acquiring an additional 676,404 shares during the last quarter. AIGH Capital Management LLC acquired a new position in shares of Delcath Systems in the 4th quarter valued at $4,918,000. Stonepine Capital Management LLC grew its stake in shares of Delcath Systems by 81.2% during the 3rd quarter. Stonepine Capital Management LLC now owns 686,240 shares of the company’s stock valued at $2,779,000 after buying an additional 307,453 shares during the period. Vanguard Group Inc. grew its stake in shares of Delcath Systems by 31.0% during the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after buying an additional 161,678 shares during the period. Finally, Worth Venture Partners LLC acquired a new stake in shares of Delcath Systems during the 4th quarter worth $1,224,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Recommended Stories

• Five stocks we like better than Delcath Systems
• How to Buy Cheap Stocks Step by Step
• How to Buy the Dip and Sell the Rip on Your Stocks with Options
• Using the MarketBeat Stock Split Calculator
• 3 Hot Buyback Plans Supporting Price Action in 2024
• How to Calculate Options Profits
• Stocks With Subscription Based Revenue Offer Inflation Protection

Receive News & Ratings for Delcath Systems Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Delcath Systems and related companies with MarketBeat.com’s FREE daily email newsletter.

You might be interested in: